✦ LIBER ✦

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

✍ Scribed by Koolen, S. L. W.; Witteveen, P. O.; Jansen, R. S.; Langenberg, M. H. G.; Kronemeijer, R. H.; Nol, A.; Garcia-Ribas, I.; Callies, S.; Benhadji, K. A.; Slapak, C. A.; Beijnen, J. H.; Voest, E. E.; Schellens, J. H. M.

Book ID: 126265135
Publisher: American Association for Cancer Research
Year: 2011
Tongue: English
Weight: 378 KB
Volume: 17
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-11-0353

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of oral gemcitabine prodru

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors

✍ Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 294 KB

Phase 1 dose escalation and pharmacokine

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

✍ Salazar, Ramon; Morales, Serafin; Gil-Martín, Marta; Aguirre, Elena; Oaknin, Ana 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 397 KB

A Phase I study of pazopanib in combinat

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

✍ Ruth Plummer, Ayman Madi, Melinda Jeffels… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 266 KB

A phase I trial of gemcitabine in combin

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

✍ William Schelman; Sherry Morgan-Meadows; Howard Bailey; Kyle Holen; James P. Tho 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 325 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Phase I study of cetuximab, erlotinib, a

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

✍ Chia-Chi Lin; Emiliano Calvo; Kyriakos P. Papadopoulos; Amita Patnaik; John Sara 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 278 KB